Up to 30 million doses of a COVID-19 vaccine could be available to the UK by September if the vaccine candidate developed by Oxford University proves successful in human trials, the government has said.
Business Secretary Alok Sharma said the first clinical trials were “progressing well” and that all phase one volunteers had received their vaccine dose “on schedule earlier this week”.
Researchers at the Oxford Vaccine Group began testing the vaccine candidate, called ChAdOx1 nCoV-19, in humans last month, 24 April, to see whether it can protect healthy people from COVID-19.
The programme will allow researchers to assess the safety of the candidate, and its ability to generate an immune response.
The vaccine will be given to half the participants, while the remaining volunteers are given a licensed meningitis vaccine to be used as a control.
When analysing results, statisticians will compare the number of infections in the control group with the number of infections in the vaccinated group. Therefore, it is necessary for a small number of study participants to develop COVID-19.
There are various vaccine candidates being trialled currently. In the UK, Imperial College London is also progressing with its vaccine candidate and will look to move into clinical trials by mid-June, with larger scale trials in October.
A thousand healthy volunteers involved in the trial
For the Oxford Vaccine Group testing, up to 1,102 participants have been recruited across multiple study sites in Oxford, Southampton, London and Bristol.
Volunteers must be aged 18-55, and cannot have tested positive for COVID-19.
They must also be in good health, not be pregnant or breastfeeding, and must not have previously taken part in a trial with an adenoviral vaccine or received any other coronavirus vaccines.
The volunteers have been randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine or a licensed meningitis vaccine that will be used as a control for comparison.
The dose used in the trial was chosen based on previous experiences with other ChAdOx1-based vaccines.
Participants will not know whether they have received the COVID-19 vaccine or the control vaccine until the end of the trial.
On April 24, the first two participants were vaccinated, one with the ChAdOx1 nCoV-19 vaccine and one with the control vaccine. On day three, six more volunteers were vaccinated, half with the COVID-19 vaccine and three with the control vaccine. On the fifth day, researchers began vaccinating larger numbers of participants.
Need a break from coronavirus news? Read some feel-good stories:
How quickly researchers reach the numbers required depends on the levels of virus transmission in the community.
If transmission remains high, enough data may be available in a couple of months but if transmission levels drop, this could take up to six months.
What is the Oxford vaccine candidate made of?
The vaccine candidate ChAdOx1 nCoV-19 is made from a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees, called ChAdOx1.
The adenovirus has been genetically changed so it is impossible for it to grow in humans.
Coronaviruses, such as the one that causes COVID-19, have an outer coat of protein spikes – recognisable in images of the virus. These spikes are what attach to the proteins on human respiratory cells, enabling the virus to enter and infect them.
The researchers vaccine candidate contains the genetic code of the protein spikes found on the coronavirus. They hope this will make the body recognise and develop an immune response to the spike protein that will help stop COVID-19 from entering human cells and therefore prevent infection.
Amy is the Editorial Assistant at BBC Science Focus and looks after all things books, culture and media. She is also a regular interviewer on the Science Focus Podcast. Her interests range from natural history and wildlife, to women in STEM and accessibility tech.